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ABSTRACT 
Topiramate is a sulfa-containing drug which is able to disrupt the ocular blood barrier. Recently it has gained 
more popularity, being used in many clinical conditions. Nowadays, the cases of glaucoma induced by topiramate 
have increased due to the use of this drug to induce weight loss. We here described a 29-year-old female 
presented with a one-day history of blurred vision in both eyes and headache. She was using a weight loss 
formula containing topiramate 100 milligrams. Ophthalmologic exam revealed an important myopic shift of -7.00 
spherical diopters at presentation with intraocular pressure (IOP) of 32 mmHg and a shallow anterior chamber in 
both eyes. After discontinuous of topiramate and use of cycloplegic eyedrops, myopic shift improved and IOP 
controlled after two days. The anterior chamber was significantly deeper in both eyes after two weeks. It is 
theorized that topiramate can provoke a ciliochoroidal effusion and, therefore, can cause an anterior 
displacement of lens-iris diaphragm with a secondary angular closure. The treatment must include cycloplegic 
and discontinuation of the drug. Sulfa-containing drugs lead to an indirect mechanism of angle closure, 
frequently bilateral and, as mentioned above, with a different treatment approach. If unrecognized and 
untreated, it can provoke high morbidity with possibility of bilateral permanent visual loss. 
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INTRODUCTION
Glaucoma is the most common form of optic neuropathy 
described as progressive loss of retinal ganglion cells 
(RGCs) as well as typical changes to the retinal nerve 
fiber layer (RNFL) and optic nerve [1, 2]. Depending on 
the angle presentation at gonioscopy, it is classified as 
open-angle or closed-angle glaucoma. Also, if an 
underlying cause is identified, it is recognized as 
secondary glaucoma. Considering closed-angle glaucoma 
features, secondary drug-induced is a rare entity with a 
high potential of permanent visual loss. Medications 
have two mechanisms to produce acute closed-angle 
glaucoma, a direct effect due to pupillary dilation or an 
indirect effect due to blood-ocular barrier disruption and 
choroidal and ciliary body effusion. For the second 
mechanism, sulfa-containing drugs are the most related 
medication class, including antibiotics (trimethoprim-
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sulfamethoxazole), diuretics (hydrochlorothiazide, 
acetazolamide and furosemide), rheumatologic drugs 
(sulfasalazine) and other drugs like topiramate, 
chlorpropamide, and sumatriptan [3, 4]. Topiramate is a 
sulfamate-substituted monosaccharide with large use in 
general medicine. It was first developed to be an 
antiepileptic medication, but recently it has gained more 
popularity, being used to treat migraine, depression, 
neuropathic pain and also for weight loss. In 2001, it was 
recognized that acute closed-angle glaucoma is a certain 
adverse side effect of the drug [5]. Nowadays, the cases 
of glaucoma induced by topiramate have increased due 
to the use of this drug to prevent migraine or induce 
weight loss [6-9].  
In this article, we illustrate one case of topiramate-
induced bilateral acute angle closure glaucoma and 
myopic shift. Also, we discuss some management 
controversies and provide literature review about this 
entity.  
CASE REPORT 
This is a case report of a 29-year old Caucasian woman 
evaluated in 2016. The present study was conducted in 
glaucoma clinics at Federal University of São Paulo. A 
written informed consent was obtained from the patient. 
Also, it was performed in accordance with the tenets of 
the Declaration of Helsinki. The patient presented with a 
one-day history of decreased visual acuity in both eyes 
(OU) described as blurring of vision and associated with 
headache. She denied any personal, ophthalmological, 
and family medical history. She was using a weight loss 
formula containing one-hundred milligrams of 
topiramate that she started a few days before. 
Ophthalmologic examination on admission revealed a 
count fingers visual acuity that improved to 0.4 logMAR 
in OU with refraction of -7.00 spherical diopters in OU. 
Her previous spectacles prescription was of -2.25 
cylindrical diopters at 180 degrees in the right eye (OD) 
and -2.75 cylindrical diopters at 180 degrees in the left 
eye (OS). Slit lamp exam demonstrated a bilateral 
shallow anterior chamber (AC) without synechiae or 
inflammation signs. The pupillary reflex was normal in 
OU. The intraocular pressure (IOP) was 32 mmHg in OU. 
Gonioscopy revealed closed angle in OU. The pachymetry 
exam was 579 micrometer (µm) in OD and 565 µm in OS. 
On fundoscopy, she had a cup to disc ratio of 0.5 in OD 
and 0.4 in OS. Anterior segment optical coherence 
tomography (OCT) revealed an appositional angle closure 
(Fig 1) and AC measurements of 2.64 millimeters (mm) in 
the OD and 2.55 mm in the OS. The pachymetry exam 
was 579 micrometer (µm) in OD and 565 µm in OS. (Fig 
2A). 
The treatment was started with tropicamide 1% every 8 
hours in OU as well as timolol maleate 0.5% and 
brinzolamide 1% every 12 hours in OU. Topiramate 
formula was also discontinued. After 40 minutes of 
cycloplegic instillation, the myopic shift decreased to -
4.00 spherical diopters and the IOP decreased to 22 
mmHg in OU. The patient returned for revaluation after 
two days with visual acuity improvement. Her myopic 
shift decreased, presenting with refraction of -1.00 
spherical diopter and visual acuity of 0.1 logMAR in OU. 
The IOP decreased to 5 mmHg in OD and 9 mmHg in OS. 
After that, we discontinued the timolol maleate and 
brinzolamide eyedrops.  
After two weeks, her corrected distance visual acuity 
(CDVA) was 0 logMAR in OU with refraction of -1.00 
spherical diopter and -2.75 cylindrical diopters at 175 
degrees in OD and -0.50 spherical diopter and -2.50 
cylindrical diopters at 175 degrees in OS. The IOP was 13 
mmHg in OD and 14 mmHg in OS. The AC measurements 
improved to 3.67 mm in OD and 3.60 mm in OS. The 
pachymetry exam was 528 µm in OD and 526 µm in OS. 
(Fig 2B). 
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Figure 1: Anterior segment opticalCoherence Tomography (OCT) Showing Bilateral Appositional Angle Closure. OD: Right Eye; OS: Left Eye. 
 
 
 
Figure 2: Anterior Chamber Depth (ACD) Evaluation at Admission (2A) and after Two Weeks of Treatment (2B). CCT: Central Corneal Thickness; µm: 
micrometer. 
 
DISCUSSION
We here described a 29-year-old female presented with 
a one-day history of blurred vision OU and headache. She 
was using a weight loss formula containing topiramate 
100 milligrams. She was developed myopic shift of -7.00 
spherical diopters at presentation with IOP of 32 mmHg 
and bilateral shallow AC. After discontinuous of 
topiramate and use of cycloplegic eyedrops, myopic shift 
improved and IOP controlled after two days. The AC was 
significantly deeper in both eyes after two weeks. 
In 2001, Banta et al. [5] were the first to describe a 
bilateral angle closure glaucoma and myopic changes 
caused by topiramate use. With the advancement of 
ocular ultrasound technology, it was possible to evaluate 
the underlying mechanism of ciliochoroidal effusion 
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provoked by sulfa-containing drugs [5, 10, 11]. It is 
theorized that disruption of ocular blood barrier caused 
by these drugs induces a ciliochoroidal effusion and 
anterior rotation of the ciliary body [5, 10, 11]. 
Therefore, anterior displacement of lens-iris diaphragm 
provokes angle closure and relaxation of the zonules 
cause lens thickening with a myopic shift induction [5, 10, 
11]. 
Hence, according to this mechanism, myotic drugs and 
iridectomies are not effective and should not be 
performed [12, 13]. Fraunfelder et al. [12] reviewed 115 
reports of topiramate-induced angle closure glaucoma 
and found that 38% of patients had a laser or surgical 
iridectomies indicating confusion with pupillary block, 
narrow-angle glaucoma entity. It is estimated that 
topiramate induces a five-fold risk of closed-angle 
glaucoma in patients younger than 50 years old [14]. 
The correct management is immediately discontinuous of 
topiramate and prescription of cycloplegic and 
antihypertensive eyedrops [3, 5, 6, 8, 12, 13]. During the 
follow-up, we can evaluate refraction, managing the 
myopic shift as well as the IOP and AC depth. Myotic 
agents such as pilocarpine should be avoided because 
cholinergic agents may worsen the lens-iris diaphragm 
displacement [3, 12, 13]. In addition, some reports 
suggest that the use of high doses of intravenous 
corticosteroids at the time of presentation can be 
beneficial [6, 15, 16]. Ultrasonography images can 
evaluate the ciliochoroidal effusions, helping to diagnose 
this drug-related entity [10]. Anterior segment OCT is a 
very useful tool that permits evaluation of AC depth, iris-
lens configuration and angle disposition [17, 18]. Optical 
coherence tomography is a noninvasive method that 
provides high-quality images of the anterior segment. 
The images can be analyzed and measurements of the AC 
and angle can be obtained and used for follow-up 
purposes. Previous reports recognize the importance of 
OCT to establish the diagnosis and guide the follow-up 
and therapeutic response, avoiding unnecessary 
interventions [17, 18]. In our case, it was possible to 
follow the AC depth increase of more than one mm in 
both eyes after the treatment was instituted. Ultrasound 
biomicroscopy can evaluate the same features as OCT, 
but requires cooperation by the patient, causes some 
discomfort and is operator-dependent [19]. 
As this clinical condition is better understood, many 
other ocular features are recognized and related to 
topiramate. Recent studies suggest serous retinal 
detachment, macular striae, anterior uveitis and 
panuveitis as possible associated conditions [20-24]. 
There is one report of acute myopia and glaucoma in a 7-
year-old child [25]. Also, it is well established in the 
literature that the ciliochoroidal effusion syndrome 
provoked by topiramate is an idiosyncratic reaction 
because it is a rare event [8, 12, 26], it is not dose-
dependent [8, 27] and there are controversies reports 
about rechallenge drug tests [8, 12, 26]. One recent study 
also demonstrated that the time of onset of symptoms 
can be variable, reporting a patient who developed acute 
glaucoma after 262 days of topiramate use [28]. 
CONCLUSIONS 
In summary, many drugs can lead to secondary 
glaucoma. Most drug-related events of acute angle-
closed glaucoma are related to pupillary block induced by 
sympathetic drugs or parasympathetic inhibitors. 
However, sulfa-containing drugs lead to an indirect 
mechanism of angular closure, frequently bilateral and, 
as mentioned above, with a different treatment 
approach. If unrecognized and untreated, it can provoke 
high morbidity with possibility of bilateral permanent 
visual loss. 
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